Cleo Diagnostics Outlines US Commercialization Strategy for Ovarian Cancer Test Ahead of FDA Clearance
MT Newswires Live
May 20
Cleo Diagnostics (ASX:COV) said it plans to enter the US market immediately following anticipated Food and Drug Administration (FDA) clearance for its pre-surgical ovarian cancer test, enabling early billing and real-world utilization data capture, according to a Wednesday Australian bourse filing.
The company said reimbursement will be determined via cross-walking to comparable multi-biomarker tests, which have reported reimbursements of around $500 to $900 per test, supporting initial pricing discussions.
The approach represents the first step toward securing a dedicated CPT code to support long-term reimbursement and commercial scale, the filing added.
The company's shares rose 1% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.